Atrium Therapeutics, Inc. (RNA)
$8.40+1.69%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $144M
- Beta
- 0.37
- P/E (TTM)
- -2.08
- Short % float
- 21.60%
- Days to cover
- 8.3
- SI change
- -0.1%
- 1W
- +7.14%
- 1M
- -18.84%
- vs SPY 1W
- +5.98%
- vs SPY 1M
- -21.83%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 7
- GROWTH
- 37
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-25.7%
REV YoY-
ROE-42.9%
EPS YoY-
ROA-33.2%
GROSS98
OP-410
NET-397
[VALUATION]
P/E TTM-2.08
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B0.64
P/FCF-
EV/EBITDA-0.69
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.78
ALTMAN Z-
CURR RATIO8.73
ND/EBITDA-
BETA0.37
Company news
FAQ
- What is LOPJLB’s current signal on RNA?
- LOPJLB’s latest quantitative signal on Atrium Therapeutics, Inc. (RNA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is RNA in?
- Atrium Therapeutics, Inc. (RNA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Atrium Therapeutics, Inc. (RNA) do?
- Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at…